<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436045</url>
  </required_header>
  <id_info>
    <org_study_id>11-111</org_study_id>
    <nct_id>NCT01436045</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of Intranasal Insulin Glulisine on Cognitive and Memory in Mild-Mod AD Patients.</brief_title>
  <official_title>A Double-Blind, Placebo-Controlled Single Dose Study of the Safety and Efficacy of Glulisine on Cognitive Function and Memory in Individuals Diagnosed With Probable Mild to Moderate Alzheimer's Disease/Intranasal Insulin Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of the rapidly acting intranasal
      insulin derivative (glulisine) on memory and cognition in 12 patients suffering from
      mild-moderate Alzheimer's Disease (AD) using a double-blind placebo-controlled single dose
      study. This study will further assess safety of insulin glulisine as well as the effects of
      this drug on olfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single center, phase II randomized, double-blind, placebo-controlled, cross-over study
      designed to assess the efficacy and safety of intranasally (IN) delivered insulin glulisine
      versus placebo in patients aged 65-85 with mild-moderate Alzheimer's Disease (AD). Twelve AD
      subjects (six female and six male) will be randomized to receive a single dose of either 20
      IU/IN insulin glulisine or placebo using the MAD 300 device.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cognitive Performance</measure>
    <time_frame>20 minutes post-intranasal administration</time_frame>
    <description>The results are presented as a mean number of correct responses for each cognitive assessment.
For each of these, a lower number correct is indicative of a higher cognitive deficit.
Ranges are as follows: RBANS List Learning (0-40), RBANS Story Memory (0-24), RBANS Figure Copy (0-20), RBANSLine Orientation (0-20), RBANS Semantic Fluency (0-unlimited), RBANS List Recall (0-10), RBANS List Recognition (0-20), RBANS Story Recall (0-12), RBANS Figure Recall (0-20), Digit Span Forward (0-16), Digit Span Backward (0-16), Boston Naming (0-15).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trails B - Seconds</measure>
    <time_frame>20 minutes post-intranasal administration</time_frame>
    <description>The results are presented as the number of seconds to complete Trails B. For each of these, a higher number of seconds is indicative of a higher cognitive deficit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trails B - Errors</measure>
    <time_frame>20 minutes post-intranasal administration</time_frame>
    <description>The results are presented as the mean sum of the errors during the Trails B assessment For each of these, a higher number of errors is indicative of a higher cognitive deficit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Olfactory Function</measure>
    <time_frame>60 minute post intranasal administration</time_frame>
    <description>The Sniff Magnitude Test (SMT) measures olfactory function not influenced by cognitive problems (minimal dependence on language, cognitive ability, memory, and odor naming ability). Sniff magnitude ratios are calculated as a ratio of sniff magnitudes (area under the sniff curve). Lower sniff magnitude ratios indicate more impairment.
[average sniff magnitude of malodor/average sniff magnitude to a null odor]</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Insulin glulisine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)</description>
    <arm_group_label>Insulin glulisine</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>salt water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject with a clinical diagnosis of probable AD in accordance with
             National Institute of Neurological and Communicative Disorders and Stroke and the
             Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria and
             Dementia Rating Scale (McKhann 1984).

          -  Mini-Mental State Examination (MMSE) score of 18-26.

          -  Hachinski Ischemia Score &lt; 4.

          -  Age is &gt; 65 and &lt;85 years

          -  Females must be &gt; 2 years post-menopausal or surgically sterile.

          -  Must be able to speak, read and understand English in order to comply with testing of
             cognitive function, memory and physiology.

          -  Must have a dedicated family member /caregiver, able to attend all visits and report
             on subject's status.

          -  Subject and family member/caregiver have both provided fully informed written consent
             prior to participation. In the event that subject is legally unable to provide
             informed written consent due to deterioration in cognitive abilities, fully informed
             written consent must be provided by a legally authorized representative.

          -  On a stable dose (â‰¥ 1 months) of a prescribed acetylcholinesterase inhibitor (e.g.
             donepezil, rivastigmine, galantamine) and/or memantine.

          -  A brain CT or MRI in the last 2 years compatible with the diagnosis of probable
             Alzheimer's Disease.

          -  A Clinical Dementia Rating (CDR) ranging from 1 to 2.

        Exclusion Criteria:

          -  Medical history and/or clinically determined evidence of other central nervous system
             (CNS) disorders including brain tumor, active subdural hematoma, seizure disorder,
             multiple sclerosis dementia with Lewy bodies, vascular dementia, corticobasal
             syndrome, progressive supranuclear palsy, Parkinson's disease, multiple system
             atrophy, frontotemporal dementia, normal pressure hydrocephalus, Huntington's disease,
             or Jakob-Creutzfeldt disease presenting as dementia.

          -  Personal medical history and/or clinically determined disorders: current B12
             deficiency, positive syphilis serology, chronic sinusitis or any untreated thyroid
             disease, significant head trauma, or history of difficulty with smell and/or taste
             prior to AD diagnosis.

          -  Diagnosis with any form of diabetes mellitus, actively takes insulin, or has HbA1c &gt;
             6.1 % at screening.

          -  Personal history of any of the following: moderate to severe pulmonary disease,
             congestive heart failure, significant cardiovascular and/or cerebrovascular events in
             previous 6 months, condition known to affect absorption, distribution, metabolism, or
             excretion of drugs such as any hepatic, renal or gastrointestinal disease or any other
             clinically relevant abnormality that inclusion would pose a safety risk to the subject
             as determined by Investigator.

          -  Heavy smoker (defined as smoking half a pack or more per day in the last 10 years
             prior to entry in the study).

          -  Personal history of any psychiatric illness, except major depressive disorder
             (according to Diagnostic and Statistical Manual (DSM)-IV TR) currently in remission or
             stable with treatment for &gt; 2 years, or any other psychiatric condition that inclusion
             would pose a safety risk to the subject as determined by Investigator. Patients with
             active depression (Geriatric Depression Score&gt;9) are excluded from the study.

          -  Currently taking any medications, herbals and food supplements that are determined by
             Investigator to interfere with procedural testing of cognitive function as well as
             ensure study safety.

          -  Recent change (&lt; 1 months) in prescribed acetylcholinesterase inhibitor (e.g.
             donepezil, rivastigmine, galantamine) or memantine.

          -  Current or recent drug or alcohol abuse or dependence defined by DSM-IV TR.

          -  Systolic blood pressure &gt; 160 or &lt; 90 mmHg or diastolic blood pressure &gt; 100 or &lt; 60
             mmHg at Screening.

          -  Screening laboratory results that are medically relevant and which would pose a safety
             risk to the subject as determined by Investigator.

          -  Participation in any other research study at least 3 months prior to this study.

          -  Insulin allergy.

          -  History of significant traumatic brain injury

          -  History of acute and chronic rhinitis and/or sinusitis.

          -  Legally unable to provide informed written consent due to deterioration in cognitive
             abilities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Rosenbloom, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HealthPartners Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HealthPartners Specialty Center - Center for Dementia &amp; Alzheimer's Care</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>April 9, 2015</results_first_submitted>
  <results_first_submitted_qc>September 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 19, 2015</results_first_posted>
  <last_update_submitted>September 25, 2015</last_update_submitted>
  <last_update_submitted_qc>September 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Memory</keyword>
  <keyword>Insulin glulisine</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Insulin Glulisine, Then Placebo</title>
          <description>A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
Insulin glulisine (5 minutes), Washout (1 week), Placebo (5 minutes)
Insulin glulisine: Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
Placebo: Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Insulin Glulisine</title>
          <description>A randomized, double-blind, placebo-controlled, cross-over designed - all subject will receive intervention (insulin glulisine) and placebo (saline) during separate visits.
Placebo (5 minutes), Washout (1 week), Insulin Glulisine (5 minutes)
Insulin glulisine: Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
Placebo: Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Partipants</title>
          <description>Participants who received either intranasal glulisine (0.10 milliliter (mL) in each nostril, 20 IU total) or placebo (0.10 mL in each nostril) at the 2nd or 3rd study visit.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mini Mental State Examination (MMSE)</title>
          <description>MMSE scale is 0 to 30. Lower scores indicate more severe cognitive impairment. Higher scores (27-30) indicate normal cognition.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.17" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>University of Pennsylvania Smell Inventory Test (UPSIT)</title>
          <description>UPSIT is used to test the function of an individual's olfactory system. The first 20 items (out of 40) were used. Range of 0-20. Lower scores indicate a lower functioning olfactory system. Higher scores indicate normal olfactory functioning.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cognitive Performance</title>
        <description>The results are presented as a mean number of correct responses for each cognitive assessment.
For each of these, a lower number correct is indicative of a higher cognitive deficit.
Ranges are as follows: RBANS List Learning (0-40), RBANS Story Memory (0-24), RBANS Figure Copy (0-20), RBANSLine Orientation (0-20), RBANS Semantic Fluency (0-unlimited), RBANS List Recall (0-10), RBANS List Recognition (0-20), RBANS Story Recall (0-12), RBANS Figure Recall (0-20), Digit Span Forward (0-16), Digit Span Backward (0-16), Boston Naming (0-15).</description>
        <time_frame>20 minutes post-intranasal administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-Insulin Glulisine</title>
            <description>Results of cognitive assessment after intranasal treatment with Insulin Glulisine.</description>
          </group>
          <group group_id="O2">
            <title>Post-Placebo</title>
            <description>Results of cognitive assessment after intranasal treatment with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Performance</title>
          <description>The results are presented as a mean number of correct responses for each cognitive assessment.
For each of these, a lower number correct is indicative of a higher cognitive deficit.
Ranges are as follows: RBANS List Learning (0-40), RBANS Story Memory (0-24), RBANS Figure Copy (0-20), RBANSLine Orientation (0-20), RBANS Semantic Fluency (0-unlimited), RBANS List Recall (0-10), RBANS List Recognition (0-20), RBANS Story Recall (0-12), RBANS Figure Recall (0-20), Digit Span Forward (0-16), Digit Span Backward (0-16), Boston Naming (0-15).</description>
          <units>mean total correct responses</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RBANS List Learning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.92" spread="1.32"/>
                    <measurement group_id="O2" value="16.67" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS Story Memory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.58" spread="1.17"/>
                    <measurement group_id="O2" value="8.41" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS Figure Copy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.58" spread="0.98"/>
                    <measurement group_id="O2" value="16.92" spread="3.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS Line Orientation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.25" spread="0.97"/>
                    <measurement group_id="O2" value="12.25" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS Semantic Fluency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.25" spread="1.38"/>
                    <measurement group_id="O2" value="12.5" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS List Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.42"/>
                    <measurement group_id="O2" value="1.0" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS List Recognition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.92" spread="0.69"/>
                    <measurement group_id="O2" value="14.75" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS Story Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.96"/>
                    <measurement group_id="O2" value="2.33" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBANS Figure Recall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" spread="1.84"/>
                    <measurement group_id="O2" value="4.92" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digit Span Forward</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.42" spread="0.50"/>
                    <measurement group_id="O2" value="9.0" spread="0.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Digit Span Backward</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58" spread="0.45"/>
                    <measurement group_id="O2" value="5.75" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Boston Naming Test</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.75" spread="1.05"/>
                    <measurement group_id="O2" value="11.75" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Response to intranasal Insulin Gluiline [(result post-insulin - result post-placebo)/(result post-placebo)] x 100%</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>RBANS Line Orientation</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Percent Change</param_type>
            <param_value>-15.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>7.0</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Response to intranasal Insulin Glulisine [(result post-insulin - result post-placebo)/(result post-placebo)] x 100%</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Olfactory Function</title>
        <description>The Sniff Magnitude Test (SMT) measures olfactory function not influenced by cognitive problems (minimal dependence on language, cognitive ability, memory, and odor naming ability). Sniff magnitude ratios are calculated as a ratio of sniff magnitudes (area under the sniff curve). Lower sniff magnitude ratios indicate more impairment.
[average sniff magnitude of malodor/average sniff magnitude to a null odor]</description>
        <time_frame>60 minute post intranasal administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-Insulin Glulisine</title>
            <description>Results of cognitive assessment after intranasal treatment with Insulin Glulisine.</description>
          </group>
          <group group_id="O2">
            <title>Post Placebo</title>
            <description>Results of cognitive assessment after intranasal treatment with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Olfactory Function</title>
          <description>The Sniff Magnitude Test (SMT) measures olfactory function not influenced by cognitive problems (minimal dependence on language, cognitive ability, memory, and odor naming ability). Sniff magnitude ratios are calculated as a ratio of sniff magnitudes (area under the sniff curve). Lower sniff magnitude ratios indicate more impairment.
[average sniff magnitude of malodor/average sniff magnitude to a null odor]</description>
          <units>ratio of area under the sniff curve</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="0.15"/>
                    <measurement group_id="O2" value="2.33" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trails B - Seconds</title>
        <description>The results are presented as the number of seconds to complete Trails B. For each of these, a higher number of seconds is indicative of a higher cognitive deficit.</description>
        <time_frame>20 minutes post-intranasal administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-Insulin Glulisine</title>
            <description>Results of cognitive assessment after intranasal treatment with Insulin Glulisine.</description>
          </group>
          <group group_id="O2">
            <title>Post-Placebo</title>
            <description>Results of cognitive assessment after intranasal treatment with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Trails B - Seconds</title>
          <description>The results are presented as the number of seconds to complete Trails B. For each of these, a higher number of seconds is indicative of a higher cognitive deficit.</description>
          <units>mean seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.83" spread="20.82"/>
                    <measurement group_id="O2" value="177.25" spread="21.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trails B - Errors</title>
        <description>The results are presented as the mean sum of the errors during the Trails B assessment For each of these, a higher number of errors is indicative of a higher cognitive deficit.</description>
        <time_frame>20 minutes post-intranasal administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Post-Insulin Glulisine</title>
            <description>Results of cognitive assessment after intranasal treatment with Insulin Glulisine.</description>
          </group>
          <group group_id="O2">
            <title>Post-Placebo</title>
            <description>Results of cognitive assessment after intranasal treatment with Placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Trails B - Errors</title>
          <description>The results are presented as the mean sum of the errors during the Trails B assessment For each of these, a higher number of errors is indicative of a higher cognitive deficit.</description>
          <units>mean number of errors</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.27"/>
                    <measurement group_id="O2" value="2.08" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in errors [result post-insulin - result post-placebo]</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.92</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Study Partipants</title>
          <description>Participants who received either intranasal glulisine (0.10 mL in each nostril, 20 IU total) or placebo (0.10 mL in each nostril) at the 2nd or 3rd study visit.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael H Rosenbloom, MD</name_or_title>
      <organization>HealthPartners Institute for Education and Research</organization>
      <phone>6512547900</phone>
      <email>michael.h.rosenbloom@healthpartners.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

